Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The retail industry is experiencing a recovery, with significant growth in specific segments such as beauty and jewelry, driven by consumer sentiment and innovative business models [8][30] - The launch of the AI model by Yiwu Small Commodity City is expected to enhance operational efficiency and empower merchants, indicating a shift towards technology-driven business practices [25][26] Summary by Sections Retail Market Review - The retail industry index rose by 3.28% during the week of July 21-25, outperforming the Shanghai Composite Index by 1.61 percentage points [7][14] - The brand cosmetics sector saw the highest weekly increase of 5.94%, while the jewelry sector led the year-to-date performance with a 28.93% increase [17][20] Industry Dynamics - Yiwu Small Commodity City partnered with Alibaba to initiate the AI model testing, which is expected to transform traditional trade practices and enhance global trade linkages [25][26] - Over 30,000 merchants in Yiwu are utilizing AI tools, with deep users experiencing over 30% growth in orders, showcasing the impact of AI on operational efficiency and brand enhancement [26] Investment Recommendations - Focus on high-quality companies in sectors benefiting from emotional consumption themes, including: - Gold and jewelry brands with differentiated product offerings, such as Laopuhuang and Chaohongji [8][30] - Retail enterprises adapting to trends, like Yonghui Supermarket and Aiyingshi [8][30] - Domestic beauty brands with strong growth potential, including Maogeping and Pola [8][30] - Medical beauty product manufacturers with unique pipelines, such as Aimeike and Kedi-B [8][30] Company-Specific Insights - Laopuhuang reported a revenue increase of 167.5% and a net profit increase of 253.9% in FY2024, indicating strong brand expansion [32] - Chaohongji achieved a revenue growth of 25.4% in Q1 2025, driven by its focus on fashionable jewelry targeting younger consumers [40] - Maogeping's revenue grew by 34.6% in FY2024, reflecting its position as a leading domestic high-end beauty brand [32] - Pola's revenue increased by 21.0% in FY2024, supported by a robust product lineup [32]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting the strong performance of domestic brands amid stricter regulations [1]. Core Insights - The cosmetics and medical beauty sector outperformed the market, with the Shenwan Beauty Care Index rising by 5.4% from July 18 to July 25, 2025, surpassing the Shenwan A Index by 1.2 percentage points [5][6]. - Stricter advertising regulations are expected to benefit leading domestic brands, as new rules will increase operational barriers and allow market share to concentrate among top players [11]. - The report emphasizes the importance of new product launches as brands prepare for the competitive landscape in the second half of 2025 [11]. Summary by Sections Industry Performance - The Shenwan Cosmetics Index increased by 3.4%, outperforming the Shenwan A Index by 1.2 percentage points, while the Shenwan Personal Care Index rose by 7.7%, exceeding the Shenwan A Index by 5.5 percentage points [5][6]. Key Company Highlights - Lin Qingxuan, a high-end domestic skincare brand, saw revenue grow from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with net profit turning from a loss of 6 million yuan to a profit of 187 million yuan [17]. - The company has a diverse product matrix with 188 SKUs, a robust supply chain with an annual production capacity of 40 million units, and a comprehensive OMO channel strategy [19]. Market Trends - The report notes a shift in the cosmetics market from quantity to quality, with e-commerce sales expected to account for 47% of total cosmetics sales by 2024, up from 22% in 2016 [13]. - The domestic market is witnessing a rise in local brands, with significant market share gains, particularly in the skincare segment [37]. Investment Recommendations - The report recommends several companies based on their market positioning and growth potential, including Up Beauty, Proya, and Marubi, while suggesting to pay attention to Shanghai Jahwa, Betaini, and Huaxi Biological [5].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights a moderate recovery in the beauty and cosmetics sector, with a notable performance in hair care and color cosmetics, indicating a stable growth trajectory [7][35] - The medical aesthetics sector is expected to gain momentum from the introduction of innovative products, particularly in the field of collagen and hair loss treatments [30][46] Summary by Sections Market Review - In June, the beauty and personal care index fell by 3.61%, ranking 31st among all primary industries, underperforming the market [14] - The medical aesthetics sector saw significant stock price increases for companies like Meili Tianyuan Medical Health (+64.4%), Yonghe Medical (+50.0%), and Sihuan Pharmaceutical (+13.3%) [20][26] - For the first half of 2025, the medical aesthetics sector recorded substantial gains, with Jinbo Biological (+124.6%), Yonghe Medical (+83.3%), and Meili Tianyuan Medical Health (+69.9%) leading the way [20][26] Medical Aesthetics - Jinbo Biological launched the world's first recombinant type III humanized collagen gel, HiveCOL, which is expected to revolutionize tissue regeneration [30] - Sihuan Pharmaceutical introduced new products targeting skin quality improvement and contour shaping, while Kedi's external finasteride spray received approval, marking a significant advancement in hair loss treatment [31][32] Cosmetics - The retail sales of cosmetics in the first half of 2025 reached 229.1 billion yuan, reflecting a year-on-year growth of 2.9% [35] - Online sales of cosmetics amounted to 267.83 billion yuan, growing by 11.1%, while offline sales decreased by 4.1% to 228.44 billion yuan [36] - The report emphasizes the strong performance of domestic brands in the online market, particularly on platforms like Douyin and Tmall [40][43] Investment Recommendations - The report recommends focusing on leading domestic beauty brands that are expected to gain market share, particularly in high-growth segments [46][47] - Key recommendations include companies like Shangmei Co., Ltd., Maogeping, and Pulaia, which are well-positioned to benefit from the ongoing trends in the beauty market [50]

Core Viewpoint - The company, Plant Doctor, is pursuing an A-share listing while expanding its offline store presence, contrasting with competitors focusing on direct sales and online channels [2][3]. Group 1: Business Strategy - Plant Doctor has nearly 5,000 stores in less than 10 years since its establishment in 2016, with a strategy focused on offline expansion, adding over 500 stores annually [2][3]. - The company operates 4,328 stores as of the end of 2024, with 3,830 being authorized franchise stores and only 498 being directly operated [5][9]. - The franchise model allows Plant Doctor to provide comprehensive support to franchisees, including site selection and training, without taking a cut from their sales [7][10]. Group 2: Financial Performance - From 2022 to 2024, Plant Doctor's revenue was 21.17 billion, 21.51 billion, and 21.56 billion respectively, with net profits of 1.58 billion, 2.3 billion, and 2.43 billion [18]. - The company's gross margin from 2022 to 2024 was 55.23%, 60.35%, and 58.90%, which is lower than industry averages of 66.69%, 68.28%, and 70.47% [19][20]. - The company plans to raise 998 million for marketing and brand building, with 526 million allocated for marketing channels and brand construction [14][15]. Group 3: Market Positioning - Plant Doctor emphasizes emotional value in its customer service, offering free skincare services to customers who purchase products, which enhances customer loyalty [10][11]. - The company has engaged in significant brand-building efforts, including celebrity endorsements and media appearances, to enhance its market presence [16]. Group 4: Challenges - The franchise model has led to management challenges, with several franchise stores facing penalties for regulatory violations and product quality issues [16]. - Customer complaints regarding product safety and service quality have been noted, indicating potential risks to brand reputation [16].

Group 1 - The company has been deeply engaged in the plant-based skincare market for 30 years, focusing on the "Plant Doctor" brand, and is one of the largest single-brand beauty store chains in China [4][10] - The company achieved revenue of 2.12 billion, 2.15 billion, and 2.16 billion yuan from 2022 to 2024, with a compound annual growth rate (CAGR) of 24% for net profit, indicating strong profitability [4][21] - The company has a well-established sales model that includes a mix of distribution and direct sales, with a comprehensive online and offline presence [4][25] Group 2 - The cosmetics market is steadily growing, transitioning from quantity to quality, with domestic brands, online sales, and niche segments driving growth [4][32] - The skincare segment remains dominant, accounting for 50.5% of the overall cosmetics market in China, with a market size of 271.2 billion yuan in 2024 [36][39] - E-commerce has rapidly risen, with its share of cosmetics sales increasing from 22% in 2016 to 47% in 2024, showcasing the efficiency and flexibility of online platforms [42][43] Group 3 - The company has a strong brand presence, ranking 13th in market share, and has received recognition as a leading plant-based skincare brand [47][50] - The company operates over 4,300 offline stores, providing extensive market coverage, while also achieving significant growth in online sales through platforms like Douyin and Taobao [51][55] - The company has established partnerships with research institutions to develop innovative plant-based ingredients, enhancing its product offerings [60]

Core Viewpoint - Marubi Biological has successfully passed the ISO56005 certification, emphasizing its commitment to technological innovation as a driving force for development and aiming to become an internationally influential beauty technology enterprise [1] Innovation-Driven Development - The ISO56005 standard is the first international standard for intellectual property management in China, aimed at enhancing the effectiveness of intellectual property management and innovation capabilities [1] - Marubi has established a systematic innovation management system centered on intellectual property and big data analysis, marking a strategic upgrade from "experience-based R&D" to "systematic innovation" [1] - The recent certification indicates Marubi's capability to transform intellectual property into commercial competitiveness, positioning it among the top tier in the beauty industry for innovation management and intellectual property integration [1] Strategic Transformation - Founded in 2002 and listed in 2019, Marubi focuses on skin science and biological research, with its main business encompassing the R&D, design, production, sales, and service of various cosmetics [2] - The company has deepened its technological innovation strategy, leveraging cutting-edge technologies like big data and artificial intelligence for R&D and product innovation [2] - In 2024, Marubi applied for 86 new domestic and international patents, with a total of 596 patent applications, including 475 invention patents, and has obtained 319 authorized patents, ranking high in the beauty industry for patent reserves [2] Market Operations - In 2024, Marubi's online channel revenue reached 2.541 billion yuan, a year-on-year increase of 35.77%, accounting for 85.61% of total revenue, while offline channel revenue was 427 million yuan, up 20.79%, making up 14.39% of total revenue [3] - The company has experienced rapid revenue and profit growth for nine consecutive quarters since its channel transformation, with plans to further solidify online transformation results [3] - Marubi's stock name changed from "Marubi Co., Ltd." to "Marubi Biological" in December 2024, reflecting its strategic shift towards becoming a biotechnology beauty company [3] Steady Development - In Q1 2025, Marubi achieved revenue of 847 million yuan, a year-on-year increase of 28.01%, and a net profit attributable to shareholders of 135 million yuan, up 22.07% [4] - For 2024, the company reported revenue of 2.97 billion yuan, a 33.44% increase, and a net profit of 342 million yuan, growing by 31.69% [4] - The main brand "Marubi" generated revenue of 2.055 billion yuan in 2024, a 31.69% increase, while the second brand "PL Love Fire" achieved 905 million yuan, up 40.72% [4] - The overall gross margin for 2024 reached 73.7%, an increase of 3.01 percentage points from 2023, attributed to optimized product structure and cost control [4]

| 昨日涨跌幅后五行业 | | --- | 2025 年 07 月 02 日 他 研 究 开源晨会 0702 ——晨会纪要 沪深300 及创业板指数近1年走势 数据来源：聚源 -16% 0% 16% 32% 48% 64% 2024-07 2024-11 2025-03 沪深300 创业板指 昨日涨跌幅前五行业 | 行业名称 | 涨跌幅(%) | | --- | --- | | 综合 | 2.601 | | 医药生物 | 1.804 | | 银行 | 1.535 | | 有色金属 | 1.489 | | 公用事业 | 1.046 | | 数据来源：聚源 | | | 行业名称 | 涨跌幅(%) | | --- | --- | | 计算机 | -1.182 | | 商贸零售 | -0.788 | | 通信 | -0.452 | | 传媒 | -0.376 | | 电力设备 | -0.373 | 数据来源：聚源 吴梦迪（分析师） wumengdi@kysec.cn 证书编号：S0790521070001 观点精粹 总量视角 【宏观经济】"两重"接力支撑 PMI，预计 Q2 GDP 约 5.2%——兼评 6 月 PM ...

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Views - The report highlights the strong performance of high-end brands and emerging effective brands in the beauty and medical aesthetics sectors, particularly during the 618 shopping festival, which saw a total e-commerce sales of 8,556 billion yuan, a year-on-year increase of 15.2% [8][36] - The medical aesthetics market is expected to grow significantly with the approval of new products, such as the first compliant lipolytic injection in China, which is projected to expand the market from 135 million yuan in 2023 to 805 million yuan by 2025 [31][32] Summary by Sections Market Review - The beauty care index rose by 2.55% in May 2025, ranking 14th among all primary industries, underperforming the overall market [16] - In May, the top performers in the medical aesthetics sector included Kedi-B (+61.3%), Sihuan Pharmaceutical (+36.1%), and East China Pharmaceutical (+15.1%) [21][26] - In the cosmetics sector, the leading companies were Lafang Jiahua (+28.0%), Shuiyang Co. (+24.5%), and Babi Co. (+19.1%) [27][29] Medical Aesthetics - The approval of Mai Nuo Wei's "Xian Su" injection marks a significant breakthrough in the domestic lipolytic market, with a projected market size increase to 8.05 billion yuan by 2025 [31][32] - The exit of CPE as a major shareholder in Meili Tianyuan is expected to optimize the company's governance structure and enhance its market position [32] Cosmetics - The 618 shopping festival saw a total GMV of 659.09 billion yuan in the beauty category, with international high-end brands showing resilience and growth due to strong brand effects [8][41] - Domestic brands like Pechoin and Han Shu led the sales on platforms like Tmall and Douyin, with significant growth rates for new brands [44] Investment Recommendations - The report recommends focusing on strong domestic beauty brands and those benefiting from high-growth segments, highlighting companies like Shangmei Co., Maogeping, and Pechoin as key investment opportunities [47][48] - In the medical aesthetics sector, companies like Aimeike and Kedi-B are recommended for their potential growth driven by new product launches and market expansion [47][48] Market Trends - The report notes a shift towards "emotional consumption" in the beauty sector, with consumers increasingly seeking products that offer aesthetic and therapeutic benefits [48] - The overall market is expected to continue evolving with new product introductions and innovative marketing strategies as the industry enters a seasonal transition [49]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, indicating potential growth opportunities in the sector [2]. Core Insights - The domestic brands showcased strong performance on Douyin, with Feicui achieving a GMV of nearly 500 million, marking a new high for the year [6][12]. - The cosmetics and medical beauty sector performed in line with the market, with the Shenwan Beauty Care Index rising by 1.6% from May 30 to June 6, 2025 [6][7]. - International cosmetic companies are experiencing a decline or slowdown in growth, with L'Oréal's Q1 2025 revenue growth at 4.4%, and Estée Lauder facing a significant drop in revenue and operating profit [13][15][16]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index increased by 1.6%, while the Shenwan Cosmetics Index rose by 0.7%, slightly underperforming the Shenwan A Index [6][7]. - Domestic brands like Marubi and Yilian have shown over 50% growth in skincare, while color cosmetics brands like Caitang and Maogeping achieved over 70% growth [12]. Key Developments - Leping Medical's "童颜针" (Youthful Needle) received approval, marking a competitive entry into the domestic market for facial fillers [26]. - Furuida's synthetic royal jelly acid (10-HDA) has achieved industrialization, providing a high-purity ingredient for anti-aging products [27]. Investment Recommendations - Recommended stocks include: 1. Upstream companies with strong R&D capabilities and profitability, such as Aimeike [17]. 2. Brands benefiting from Douyin traffic, like Marubi [17]. 3. Companies with strong product innovation and cost-effectiveness, such as Runben and Furuida [17]. - Suggested to pay attention to Shanghai Jahwa, Betaini, Huaxi Biological, and Water Sheep [17]. Market Trends - The cosmetics market in China is projected to grow, with a retail sales increase of 7.2% in April 2025, indicating a recovery in consumer demand [23][25]. - The market share of domestic brands in the skincare segment has improved significantly, with domestic brands occupying five out of the top ten positions in market share [36][37].

Group 1: Market Performance - Major indices experienced a rebound on June 4, with the Shanghai Composite Index rising by 0.42%, the Shenzhen Component Index by 0.87%, and the ChiNext Index by 1.11% [2] - Over 3,700 stocks in the Shanghai and Shenzhen markets saw gains, with a total trading volume of approximately 1.15 trillion yuan [2] Group 2: Beauty and Personal Care Sector - The beauty and personal care sector showed strong performance, with companies like Haoyue Care rising by 10% and Jinbo Biological by 7.36% [2] - A report from China Merchants Securities indicated that the cosmetics sector will continue to see performance differentiation in 2024 and Q1 2025, with leading domestic brands benefiting from competitive pricing and differentiated products [2] Group 3: AI and CPO Technology - Companies involved in AI and CPO technology saw significant gains, with Taicheng Light rising by 14.88% and Xinyi Sheng by over 7% [2][3] - Yole's report predicts that the CPO market will grow from $46 million in 2024 to $8.1 billion by 2030, with a compound annual growth rate of 137% [3] Group 4: Beer Industry - The beer sector also showed strength, with companies like Pinwo Food rising by 12.84% and Huichuan Beer by over 7% [3] - Analysts noted that the beer industry is in the late stage of capital expenditure, with potential for increased dividend payouts from state-owned enterprises [3] Group 5: Battery and Solid-State Battery Sector - The battery and solid-state battery sectors were active, with Keheng Co. rising by 20% and Nord Co. by 10% [4] - Solid-state batteries are expected to start vehicle verification by 2027 and achieve mass production by 2030, with projected shipments exceeding 65 GWh by that year [4] Group 6: Declining Sectors - The logistics and airport shipping sectors faced declines, with companies like China Eastern Airlines and Shentong Express experiencing downturns [5]